Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | YARS1 | P54577 | 1/20 | 0.31 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.31 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19426106 | 0.84 | YARS1 (0.32) | ADRA2AADRA2BADRA2CADRA1AALDH1A1 | |
| SCHEMBL19426170 | 0.81 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CADRA1AYARS1 | |
| SCHEMBL19426176 | 0.78 | KMT2A (0.33) | FFAR2ADRA2AADRA2CADRA1A | |
| SCHEMBL19426169 | 0.69 | CYP1A2 (0.36) | FFAR2 | |
| SCHEMBL12380944 | 0.68 | GABRA1 (0.46) | ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL19426172 | 0.68 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL15495186 | 0.66 | SELL (0.41) | — | |
| SCHEMBL2760850 | 0.66 | ADRA2A (0.66) | ADRA2AADRA2BADRA2CADRA1AALDH1A1 | |
| SCHEMBL30557720 | 0.65 | ADRA2A (0.37) | ADRA2AADRA2BADRA2CADRA1AERCC1 | |
| SCHEMBL11850416 | 0.65 | ADRB2 (0.39) | ADRA2AADRA2BADRA2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | FFAR2 4755/4885ADRA2A 2852/4885ADRA2B 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.